利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.023 秒)

    Method, Particularly Enzyme-Linked Immunosorbent Assay (ELISA), for In Vitro Detection of Amyloid Beta Autoantibodies, Microtiter Plate, and Test Kit
    1.
    发明申请
    Method, Particularly Enzyme-Linked Immunosorbent Assay (ELISA), for In Vitro Detection of Amyloid Beta Autoantibodies, Microtiter Plate, and Test Kit 审中-公开
    方法，特别是酶联免疫吸附测定（ELISA），用于体外检测淀粉样蛋白β自身抗体，微量滴定板和测试试剂盒

    公开(公告)号：US20130109033A1

    公开(公告)日：2013-05-02

    申请号：US13384726

    申请日：2010-07-14

    申请人： Michael Bacher ,  Richard Dodel ,  Karthikeyan Balakrishnan

    发明人： Michael Bacher ,  Richard Dodel ,  Karthikeyan Balakrishnan

    IPC分类号： G01N33/53

    CPC分类号： G01N33/5306 ,  B01L3/5085 ,  B01L2300/0829 ,  G01N33/54386 ,  G01N33/564 ,  G01N33/6896 ,  G01N2800/2821

    摘要： A method, particularly an enzyme-linked immunosorbent assay (ELISA), for the in-vitro detection of Aβ autoantibodies in human serum and/or plasma contains the following steps: preparing an antigen-coated solid phase; incubating the solid phase with a blocking solution; incubating the solid phase with a sample to be examined; immunological detection of the Aβ autoantibodies on the solid phase; and reading the detected results of the solid phase using a reading tool. According to the invention, the preparation of the antigen-coated solid phase advantageously includes incubating the solid phase with a coating solution in which the antigen is dissolved, said antigen having a peptide sequence selected from the group SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3.

    摘要翻译： 用于体外检测人血清和/或血浆中Abeta自身抗体的方法，特别是酶联免疫吸附测定法（ELISA）包括以下步骤：制备抗原包被的固相; 用固定溶液孵育固相; 将固相与待检样品孵育; Abeta自身抗体在固相上的免疫学检测; 并使用读取工具读取检测到的固相的结果。 根据本发明，抗原包被的固相的制备有利地包括将固相与其中溶解抗原的包被溶液一起孵育，所述抗原具有选自SEQ ID No.1，SEQ ID No 2或SEQ ID No.3。

    Human monoclonal anti-amyloid-beta antibodies
    2.
    发明授权
    Human monoclonal anti-amyloid-beta antibodies 有权
    人单克隆抗淀粉样蛋白β抗体

    公开(公告)号：US07939075B2

    公开(公告)日：2011-05-10

    申请号：US12013185

    申请日：2008-01-11

    申请人： Richard Dodel ,  Michael Bacher ,  Michael Przybylski ,  Raluca Stefanescu ,  Marilena Manea

    发明人： Richard Dodel ,  Michael Bacher ,  Michael Przybylski ,  Raluca Stefanescu ,  Marilena Manea

    IPC分类号： A61K39/395 ,  C07K16/18

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565

    摘要： Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

    摘要翻译： 提供分离的，单克隆的，人的，抗 - 抗 - 淀粉样蛋白抗体，其以比单体形式的Ab更高的亲和力结合Ab的二聚体形式，并且当与Aβ结合时， 多肽包含蛋白水解消化的A＆bgr（21-37）屏蔽A和Bgr（21-37）。 显示抗体抑制原纤维形成并减少体内的斑块大小并且不结合脑血管壁。 因此，该抗体可用于人和兽医用于治疗和预防阿尔茨海默病和其他神经变性疾病。 还提供了检测或测量神经退行性疾病进展的方法。

    Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-B-amyloid antibody
    3.
    发明授权
    Method of treatment of neurodementing diseases using isolated, monoclonal, human, anti-B-amyloid antibody 有权
    使用分离的，单克隆抗体，人抗B淀粉样抗体治疗神经变性疾病的方法

    公开(公告)号：US08491903B2

    公开(公告)日：2013-07-23

    申请号：US13079852

    申请日：2011-04-05

    申请人： Richard Dodel ,  Michael Bacher ,  Michael Przybylski ,  Raluca Stefanescu ,  Marilena Manea

    发明人： Richard Dodel ,  Michael Bacher ,  Michael Przybylski ,  Raluca Stefanescu ,  Marilena Manea

    IPC分类号： A61K39/395

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565

    摘要： Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formulation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

    摘要翻译： 提供分离的，单克隆的，人的抗β-淀粉样蛋白抗体，其以比单体形式的Ab更高的亲和力结合Ab的二聚形式，并且当结合到包含Abeta（21-37）屏蔽Abeta（21-37） ）从蛋白水解消化。 显示抗体抑制原纤维制剂并且在体内减少斑块大小并且不结合脑血管壁。 因此，该抗体可用于人和兽医用于治疗和预防阿尔茨海默病和其他神经变性疾病。 还提供了检测或测量神经退行性疾病进展的方法。

    DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER NEURODEMENTING DISEASES
    6.
    发明申请
    DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER NEURODEMENTING DISEASES 有权
    阿尔茨海默病和其他神经病变的诊断和治疗

    公开(公告)号：US20090028869A1

    公开(公告)日：2009-01-29

    申请号：US12013185

    申请日：2008-01-11

    申请人： Richard Dodel ,  Michael Bacher ,  Michael Przybylski ,  Raluca Stefanescu ,  Marilena Manea

    发明人： Richard Dodel ,  Michael Bacher ,  Michael Przybylski ,  Raluca Stefanescu ,  Marilena Manea

    IPC分类号： A61K39/395 ,  C07K16/00 ,  G01N33/68 ,  A61P25/00

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565

    摘要： Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.

    摘要翻译： 提供分离的，单克隆的，人的抗β-淀粉样蛋白抗体，其以比单体形式的Ab更高的亲和力结合Ab的二聚形式，并且当结合到包含Abeta（21-37）屏蔽Abeta（21-37） ）从蛋白水解消化。 显示抗体抑制原纤维形成并减少体内的斑块大小并且不结合脑血管壁。 因此，该抗体可用于人和兽医用于治疗和预防阿尔茨海默病和其他神经变性疾病。 还提供了检测或测量神经退行性疾病进展的方法。